In vitro activity of ceftaroline against mecC-positive MRSA isolates

Armengol-Porta, M.; Tenorio-Abreu, A.; Bandt, D.; Coleman, D.C.; Gavier-Widen, D.; Hotzel, Helmut GND; Kinnevey, P.; Lazaris, A.; Peters, M.; Rangstrup-Christensen, L.; Schlotter, K.; Shore, A.C.; Ehricht, R.; Monecke, S.

Ceftaroline is a new cephalosporin with activity against meticillin-resistant Staphylococcus aureus (MRSA). A collection of 17 clinical and veterinary mecC-positive MRSA isolates was tested to evaluate the in vitro efficacy of ceftaroline against recently emerged mecC-MRSA isolates. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of ceftaroline for the 17 isolates were determined by broth microdilution using the methodology and interpretive criteria of the Clinical and Laboratory Standards Institute (CLSI). Additional susceptibility tests were performed using ceftaroline M.I.C.Evaluator (M.I.C.E.™) strips. All strains showed susceptibility according to CLSI breakpoints, with MICs of ceftaroline ranging from 0.125 mg/L to 0.25 mg/L. MBCs were identical or up to a two-fold dilution step higher. In conclusion, all tested isolates, from various sources and belonging to several clonal complexes (CCs), but predominantly to CC130, were found to be susceptible to ceftaroline. Ceftaroline could thus be an option for the treatment of mecC-MRSA infections.



Citation style:

Armengol-Porta, M. / Tenorio-Abreu, A. / Bandt, D. / et al: In vitro activity of ceftaroline against mecC-positive MRSA isolates. 2016.


Use and reproduction:
All rights reserved